List of Excipients in Branded Drug PIROXICAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Greenstone LLC	PIROXICAM	piroxicam	59762-0140	FD&C BLUE NO. 1
Greenstone LLC	PIROXICAM	piroxicam	59762-0140	FD&C RED NO. 3
Greenstone LLC	PIROXICAM	piroxicam	59762-0140	LACTOSE
Greenstone LLC	PIROXICAM	piroxicam	59762-0140	MAGNESIUM STEARATE
Greenstone LLC	PIROXICAM	piroxicam	59762-0140	SODIUM LAURYL SULFATE
Greenstone LLC	PIROXICAM	piroxicam	59762-0140	STARCH, CORN

Generic Drugs Containing PIROXICAM

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	piroxicam	0093-0756	AMMONIA
Teva Pharmaceuticals USA Inc	piroxicam	0093-0756	D&C YELLOW NO. 10
Teva Pharmaceuticals USA Inc	piroxicam	0093-0756	DIMETHICONE
Teva Pharmaceuticals USA Inc	piroxicam	0093-0756	FD&C BLUE NO. 1
Teva Pharmaceuticals USA Inc	piroxicam	0093-0756	FD&C GREEN NO. 3
Teva Pharmaceuticals USA Inc	piroxicam	0093-0756	FERRIC OXIDE YELLOW
Teva Pharmaceuticals USA Inc	piroxicam	0093-0756	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in PIROXICAM?

# Of NDCs	Excipient
1	AMMONIA
1	COLLOIDAL SILICON DIOXIDE
2	D&C RED NO. 28
2	D&C RED NO. 33
17	D&C YELLOW NO. 10
6	DIMETHICONE
5	ETHYLENE GLYCOL MONOETHYL ETHER

Piroxicam Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Piroxicam is an off-patent oxicam NSAID with low aqueous solubility, high protein binding, a long elimination half-life of approximately 50 hours, and established gastrointestinal, renal, cardiovascular, and hepatic safety risks. The strongest commercial opportunities are differentiated oral formulations that improve dissolution, reduce peak-related tolerability issues, support lower dosing, or target localized delivery. Broad composition-of-matter exclusivity is unavailable, so commercial value depends on formulation performance, regulatory positioning, manufacturing scale, and defensible delivery claims.

What is the current FDA and commercial status of piroxicam?

Piroxicam is marketed primarily as an oral capsule for osteoarthritis and rheumatoid arthritis. The reference product is Feldene, originally developed by Pfizer. The FDA-approved product is prescription-only and has generic competition.

Attribute	Piroxicam status
Active ingredient	Piroxicam
Therapeutic class	Oxicam NSAID
Primary indications	Osteoarthritis and rheumatoid arthritis
Original brand	Feldene
Standard oral strengths	10 mg and 20 mg capsules
Typical adult dose	20 mg once daily or 10 mg twice daily, depending on labeling
Elimination half-life	Approximately 50 hours
BCS-related development issue	Low aqueous solubility and dissolution limitation
US composition-of-matter patent	Expired
US generic competition	Established
Biosimilar exposure	None
Primary commercial barrier	Safety profile and low-cost generic pricing

The FDA labeling limits piroxicam to the lowest effective dose for the shortest duration consistent with treatment goals because of serious gastrointestinal and cardiovascular risks.[1] Its long half-life can support once-daily dosing but also prolongs exposure after adverse events or discontinuation.

Piroxicam remains commercially relevant in markets where low-cost NSAIDs are widely used and where branded or differentiated oral products can command a premium. Generic capsules have limited pricing power. New opportunities therefore depend on delivery technologies, regional regulatory pathways, and formulation-based clinical claims.

What excipient properties matter most for piroxicam?

Piroxicam has weak aqueous solubility and can exhibit slow or variable dissolution. Excipient selection should focus on improving wetting, particle dispersion, dissolution rate, manufacturability, and gastrointestinal tolerability without increasing systemic exposure unpredictably.

Key formulation targets

Formulation target	Relevant excipient function	Commercial rationale
Faster dissolution	Surfactant, wetting agent, hydrophilic polymer	May reduce food-related or patient-related variability
Improved apparent solubility	Cyclodextrin, cosolvent, pH modifier	Enables liquid, oral-film, or rapidly dissolving products
Particle dispersion	Colloidal silicon dioxide, coprocessed excipient, polymeric carrier	Supports content uniformity and dissolution
Controlled release	Hydrophilic matrix polymer, lipid matrix, coating polymer	Could reduce peak exposure or extend dosing control
Taste masking	Ion-exchange resin, polymer coating, lipid barrier	Important for pediatric or orally disintegrating products
Gastrointestinal protection	Enteric polymer, delayed-release coating, local protective excipient	May reduce direct gastric exposure but does not remove systemic NSAID risk
Physical stability	Antioxidant, chelator, moisture barrier, desiccant packaging	Protects potency and dissolution over shelf life
Topical delivery	Solubilizer, penetration enhancer, gel former, emulsion system	Enables localized pain treatment and lower systemic exposure

Piroxicam formulation development must distinguish improved dissolution from increased systemic exposure. A faster-dissolving formulation can raise early plasma concentrations and potentially worsen adverse-effect risk. The commercial objective is not simply higher bioavailability. It is controlled, reproducible exposure with a clinically meaningful benefit.

Which excipients are most promising for piroxicam solubility enhancement?

Cyclodextrins and piroxicam inclusion complexes

Cyclodextrins are among the most commercially credible excipient platforms for piroxicam. Piroxicam can form inclusion complexes with cyclodextrins, particularly beta-cyclodextrin derivatives such as hydroxypropyl-beta-cyclodextrin. These systems can improve apparent aqueous solubility, wetting, dissolution, and in some cases onset of action.

Potential products include:

• Piroxicam-beta-cyclodextrin tablets
• Rapid-dissolution granules
• Oral powders or sachets
• Oral liquids
• Buccal or sublingual dosage forms
• Injectable or parenteral systems where excipient safety permits

The main development risks are complex stoichiometry, moisture sensitivity, high excipient loading, variable complexation during scale-up, and the need to demonstrate a clinically relevant advantage over low-cost capsules. Cyclodextrin products also require careful assessment of renal handling, route-specific tolerability, and permitted exposure levels.

Surfactants and wetting agents

Polysorbates, sodium lauryl sulfate, poloxamers, and other surfactants can improve wetting and dissolution. They are most useful in low-dose solid formulations, wet granulation, lipid-based systems, and oral suspensions.

Surfactant selection requires control of:

• Micelle formation
• Drug precipitation after dilution
• Oxidative degradation
• Gastrointestinal tolerability
• Tablet hardness and disintegration
• Batch-to-batch dissolution

Surfactants alone may produce a strong in vitro effect that does not persist after gastrointestinal dilution. A polymer-surfactant combination is often more robust than a surfactant-only approach.

Hydrophilic polymers and amorphous solid dispersions

Polyvinylpyrrolidone, copovidone, hydroxypropyl methylcellulose, and Soluplus-type polymers can maintain piroxicam in an amorphous or supersaturated state. Spray drying, hot-melt extrusion, and solvent evaporation are potential manufacturing routes.

The primary risk is recrystallization during storage or after administration. A formulation that achieves high initial dissolution but rapidly precipitates may not produce a reliable pharmacokinetic benefit. Stabilizer selection, residual solvent limits, glass-transition behavior, humidity control, and packaging are central development issues.

Lipid-based delivery systems

Self-emulsifying drug delivery systems and lipid suspensions can improve dispersion of poorly soluble piroxicam. Medium-chain triglycerides, mono- and diglycerides, phospholipids, and nonionic surfactants are potential components.

Lipid systems may support:

• Soft gelatin capsules
• Liquid-filled hard capsules
• Oral emulsions
• Topical emulsions
• Intramuscular depot concepts

Their commercial drawbacks include capsule compatibility, oxidation, leakage, fill-weight control, and relatively complex manufacturing. The product must also demonstrate that improved solubilization does not generate an unacceptable early concentration spike.

What formulation opportunities exist for piroxicam?

Immediate-release tablets and capsules

A direct generic capsule is the lowest-risk path but has limited differentiation. An improved immediate-release tablet can compete through:

• Faster dissolution
• Smaller tablet size
• Lower excipient burden
• Better content uniformity
• Reduced manufacturing cost
• Regional substitution for imported products

A formulation patent based only on routine disintegrants, lubricants, or standard wet granulation is likely to face obviousness challenges. Stronger protection requires a defined excipient ratio, measurable dissolution profile, stability advantage, or clinically demonstrated pharmacokinetic result.

Orally disintegrating tablets

Orally disintegrating piroxicam products may address patients with dysphagia, elderly patients, and settings where water is unavailable. Candidate excipients include crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, mannitol, sorbitol, silicified microcrystalline cellulose, and taste-masking polymers.

The principal technical problem is taste. Piroxicam is unsuitable for an unmasked oral-dispersible product if the drug remains in contact with the tongue. A taste-masked particle or coated granule is likely required.

A differentiated orally disintegrating tablet could be protected through claims covering:

• Coated piroxicam particles
• Defined disintegration time
• Specified dissolution after oral dispersion
• Taste-masking layer composition
• Moisture-stable packaging
• A manufacturing process that preserves particle coating integrity

Liquid and pediatric formulations

Piroxicam is not a natural first-choice pediatric NSAID because of its long half-life and safety profile. A liquid formulation could still have niche value in markets where pediatric or swallowing-related demand exists, but the clinical and regulatory case is weaker than for adult dosage-form differentiation.

Potential excipients include suspending agents, wetting agents, sweeteners, flavors, preservatives, and pH modifiers. A suspension may be preferable to a solution when solubilization would require high cyclodextrin or surfactant levels.

Commercial risks include sedimentation, dose uniformity, preservative acceptance, microbial control, and the need to justify the target population.

Topical gels and creams

Topical piroxicam is the clearest opportunity for a non-oral product. Topical NSAIDs can provide localized treatment while reducing systemic exposure relative to oral NSAIDs, although systemic absorption and local adverse reactions remain relevant.

Potential excipient systems include:

• Carbomer or cellulose-based gels
• Propylene glycol and polyethylene glycol cosolvents
• Ethanol-water systems
• Phospholipid emulsions
• Liposomes
• Microemulsions
• Nanoemulsions
• Penetration enhancers such as oleic acid or selected terpenes

A topical product must establish consistent skin permeation, acceptable irritation, dose delivery per application, and stability. The strongest intellectual-property position would combine a defined piroxicam concentration with a specific vehicle, permeation profile, and clinical indication.

Topical products face substantial regulatory variation. Some jurisdictions recognize topical piroxicam products, while others may require a new drug application, hybrid application, or local clinical evidence because the topical product is not therapeutically equivalent to an oral capsule.

Controlled-release and gastroretentive products

Piroxicam already has a long half-life, so controlled release is not an obvious value proposition. A sustained-release product could reduce peak concentrations, but the extended exposure profile may complicate management of adverse events.

A controlled-release formulation would require evidence that it improves tolerability, reduces peak-to-trough variation, or improves adherence. Standard hydrophilic matrices alone are unlikely to justify premium pricing or strong patent protection.

Enteric-coated products

Enteric coating may reduce drug release in the stomach, but it does not eliminate systemic gastrointestinal, renal, or cardiovascular risks. It can also delay onset and produce variable release depending on gastric emptying and intestinal conditions.

Enteric-coated piroxicam can have a targeted use case for patients with gastric sensitivity, but the clinical benefit must be demonstrated rather than assumed. Suitable coating polymers include methacrylic acid copolymers, cellulose acetate phthalate, and related enteric systems.

What patents protect piroxicam formulations?

Piroxicam's original active-ingredient exclusivity has expired. Current commercial protection is more likely to arise from formulation, delivery, manufacturing, or use claims than from the molecule itself.

Patent category	Current relevance	Typical strength
Composition of matter	Expired	None for new entrants
Basic oral capsule	Generally weak or expired	Low
Cyclodextrin complex	Potentially relevant in narrow jurisdictions or later-filed families	Moderate if claims are specific
Amorphous dispersion	Potentially protectable	Moderate, dependent on prior art
Orally disintegrating formulation	Protectable if taste masking and performance are specific	Moderate
Topical gel or emulsion	Commercially relevant	Moderate to strong if clinically differentiated
Manufacturing process	Can block efficient production	Moderate
Method of treatment	Narrow and vulnerable to invalidity or use restrictions	Low to moderate
Packaging and stability	Usually supplementary	Low

A new piroxicam patent must satisfy novelty, inventive step or non-obviousness, written description, enablement, and industrial applicability requirements. The prior-art field is mature. Generic excipient substitutions are unlikely to support broad claims.

How strong is the patent estate for piroxicam?

The molecule-level estate is weak because piroxicam has been marketed for decades. A new estate can be commercially meaningful only when it protects a product-specific combination that is difficult to design around.

The most defensible claim elements include:

• A narrow excipient ratio
• A specified dissolution window
• Particle-size or solid-state limitations
• A defined complexation level
• A clinically demonstrated reduction in peak plasma concentration
• A topical permeation range
• A manufacturing sequence that produces a non-obvious performance result
• Stability under accelerated and long-term conditions

Freedom-to-operate analysis should cover expired piroxicam patents, active formulation families, cyclodextrin technology, topical delivery patents, coating systems, and excipient supplier licenses.

When does piroxicam lose exclusivity?

Piroxicam already lost primary market exclusivity in the United States and major pharmaceutical markets. No biosimilar pathway applies because piroxicam is a small molecule rather than a biologic.

Exclusivity type	Piroxicam position
New chemical entity exclusivity	Expired
Composition-of-matter patent	Expired
FDA generic entry	Established
Pediatric exclusivity	No material current barrier
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
New formulation exclusivity	Possible only for a newly approved differentiated product
Three-year clinical-investigation exclusivity	Potentially available for a qualifying new application
Five-year NCE exclusivity	Not available for the old active ingredient

A reformulated piroxicam product may qualify for regulatory exclusivity only if it satisfies applicable FDA requirements for a new drug application and includes qualifying new clinical investigations. An abbreviated new drug application for a conventional generic does not create the same commercial exclusivity.

What Paragraph IV and litigation risks affect piroxicam?

Piroxicam has a long generic history, so conventional Paragraph IV risk is less important than formulation-specific patent disputes. A new branded formulation could face challenges from generic manufacturers seeking approval before expiration of newly issued patents.

Potential litigation issues include:

• Whether the formulation claims are obvious in view of known NSAID excipient systems
• Whether a generic product infringes a dissolution or composition limitation
• Whether a listed method-of-use claim is properly tied to labeling
• Whether the patent owner has complied with Orange Book listing requirements
• Whether a product is eligible for substitution under state pharmacy law
• Whether topical and oral products are therapeutically equivalent

For a new FDA-approved formulation, Orange Book listing may be available for patents that claim the drug substance, drug product, or approved method of use, subject to FDA rules.[2] Process patents generally do not provide the same Orange Book leverage.

Settlement agreements would be relevant only if a new formulation creates a meaningful branded market. Existing generic piroxicam products do not create a major current settlement landscape comparable to newer high-revenue medicines.

What is the Orange Book status of piroxicam?

The Orange Book historically listed Feldene and approved generic piroxicam products. The practical commercial position is generic availability, with no broad active patent barrier preventing standard oral entry.

Orange Book diligence should distinguish:

• The original Feldene listing
• Current approved generic capsules
• Any active patents for new dosage forms
• Discontinued or withdrawn products
• Product-specific therapeutic-equivalence ratings
• Patent listings associated with later reformulations

A company evaluating a new piroxicam product should not assume that the absence of a broad active patent estate prevents later formulation patents. It does mean that any new patent must be evaluated against extensive prior art and an established generic reference market.

What commercial opportunities exist for piroxicam?

Opportunity ranking

Opportunity	Market need	Development complexity	IP potential	Commercial outlook
Low-cost oral generic	Moderate	Low	Low	High-volume, low-margin
Fast-dissolving oral product	Moderate	Moderate	Moderate	Selective
Taste-masked orally disintegrating tablet	Niche	Moderate	Moderate	Specialty
Cyclodextrin oral formulation	Moderate	Moderate	Moderate	Regional premium
Topical gel or emulsion	High	Moderate	Moderate to strong	Most attractive
Controlled-release oral product	Low to moderate	High	Moderate	Limited
Pediatric liquid	Low	Moderate	Low to moderate	Narrow
Hospital injectable	Low	High	Moderate	Limited

Regional opportunities

Commercial potential is highest where:

• Oral piroxicam remains widely prescribed
• Topical NSAIDs have strong pharmacy demand
• Local manufacturing is favored
• Imported branded products are expensive
• Regulatory pathways recognize well-established active ingredients
• Generic substitution is less price-compressed

A topical or cyclodextrin-based product may command a premium in markets where conventional piroxicam capsules are inexpensive but patients value easier administration or localized therapy.

What manufacturing and IP barriers should companies expect?

The main manufacturing barriers are not raw-material scarcity. They are control of solid state, dissolution, content uniformity, moisture, and scale-up reproducibility.

Critical process controls include:

• API particle size and polymorphic form
• Milling energy and thermal exposure
• Granulation endpoint
• Excipient distribution
• Coating weight gain
• Residual solvent
• Moisture uptake
• Capsule fill variation
• Dissolution after accelerated stability testing

For cyclodextrin products, the process must control complex formation rather than simply blend the two components. For amorphous dispersions, recrystallization monitoring is essential. For topical products, viscosity, droplet size, drug partitioning, and skin permeation must remain consistent across scale.

Excipient suppliers may control proprietary grades, technical know-how, or formulation platforms. A license may be required for certain lipid systems, spray-dried dispersions, coated-particle technologies, or advanced topical delivery systems.

How does piroxicam compare with other NSAIDs?

Drug	Half-life	Solubility/formulation issue	Differentiation opportunity
Piroxicam	About 50 hours	Poor solubility and prolonged exposure	Topical delivery, controlled dissolution
Diclofenac	About 1-2 hours	Multiple salts and dosage forms	Topical, modified release, combination products
Naproxen	About 12-17 hours	Low solubility	Salt selection, suspension, topical products
Meloxicam	About 15-20 hours	Low solubility	Oral suspension, ODT, pediatric positioning
Ibuprofen	About 2 hours	Dose size and solubility	Liquids, lysine salt, fast onset
Celecoxib	About 11 hours	Poor solubility	Amorphous dispersion, capsule technology

Piroxicam's long half-life is both a benefit and a constraint. It supports once-daily administration but reduces the attractiveness of formulations designed only to extend release. Compared with diclofenac and ibuprofen, piroxicam has fewer broad consumer opportunities because its safety profile and prolonged systemic exposure limit mass-market repositioning.

Key Takeaways

• Piroxicam has no meaningful remaining composition-of-matter exclusivity.
• Conventional oral capsules are mature generic products with limited pricing power.
• The strongest excipient opportunity is improved dissolution without uncontrolled increases in systemic exposure.
• Cyclodextrins, hydrophilic polymers, surfactants, and lipid systems are technically credible platforms.
• Topical gels, emulsions, and advanced transdermal systems offer the clearest commercial differentiation.
• Orally disintegrating products require effective taste masking and moisture control.
• Controlled-release products face a weak value proposition because piroxicam already has a long half-life.
• New patent value depends on narrow, measurable formulation performance rather than routine excipient selection.
• Piroxicam has no biosimilar risk.
• Orange Book and Paragraph IV analysis matters mainly for newly approved reformulations, not established generic capsules.
• The most attractive strategy is a topical or rapidly dissolving product supported by clinical evidence of improved tolerability, administration, or localized treatment.

FAQs

Can cyclodextrin improve piroxicam bioavailability?

Cyclodextrin can improve apparent solubility and dissolution. The impact on bioavailability depends on complex stability, gastrointestinal dilution, precipitation, and formulation design. Increased exposure is not automatically beneficial because piroxicam has dose-related safety concerns.

Is piroxicam suitable for an orally disintegrating tablet?

Yes, but taste masking is necessary. A coated-particle, polymeric, or lipid barrier system is more commercially credible than an unmasked directly compressible formulation.

Are piroxicam topical products patentable?

Yes. Patentability may arise from a specific vehicle, excipient ratio, particle or droplet structure, permeation profile, manufacturing process, or clinically demonstrated reduction in systemic exposure. Broad claims to topical piroxicam alone are vulnerable to prior art.

Does piroxicam qualify for a 505(b)(2) development strategy?

A reformulated piroxicam product may be a candidate for a 505(b)(2) pathway if it relies partly on FDA findings for an approved reference product while introducing a new dosage form, route, formulation, or delivery system. The pathway and exclusivity depend on the product's clinical and regulatory package.

What is the best commercial excipient strategy for piroxicam?

The strongest strategy is a product-specific system combining a solubility or delivery excipient with measurable clinical or pharmaceutical performance. In practice, this most likely means a topical gel or emulsion, a taste-masked orally disintegrating tablet, or a cyclodextrin-enabled rapidly dissolving oral product.

References

1. U.S. Food and Drug Administration. (2023). Feldene (piroxicam) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. National Library of Medicine. (2024). Piroxicam drug label. DailyMed.

4. European Medicines Agency. (2006). Assessment report for piroxicam-containing medicinal products. EMA.

5. Loftsson, T., & Brewster, M. E. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. Journal of Pharmaceutical Sciences, 85(10), 1017-1025.

6. U.S. Food and Drug Administration. (2019). Guidance for industry: Regulatory classification of pharmaceutical co-crystals. FDA.